Document is current
Any future updates will be listed below
-
Authors
Miloushev, Vesselin Z. https://orcid.org/0000-0002-1899-8791
Boltyanskiy, Rostislav
Granlund, Kristin L.
Keshari, Kayvan R.
-
Funding
Funding for this research was provided by:
National Institutes of Health (NIH P30 CA008748, R01 CA195476, R01 CA237466)
Dana Foundation
MSKCC Internal Grant (Radiology Development Project)
- License Information
-
More Information
Article History
Received: 12 January 2022
Revised: 10 June 2022
Accepted: 23 June 2022
First Online: 25 July 2022
Declarations
:
: The authors have no conflicts of interest related to this work. Patients were recruited under an institutional review board-approved protocol (IRB 14–205, PI: Keshari) at Memorial Sloan Kettering Cancer Center (MSKCC). An investigational drug acknowledgement was granted for HP [1 − 13C] pyruvate (IND #11259470, PI: Keshari). Written, informed consent was documented.
: The study was performed in accordance with the Declaration of Helsinki, Belmont Report, U.S. Common Rule guidelines, and the International Ethical Guidelines for Biomedical Research Involving Human Subjects. All information was accessed, stored, and published in keeping with HIPAA protections.
